|
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
RECRUITINGPhase 2Sponsored by National Taiwan University Hospital
Actively Recruiting
PhasePhase 2
SponsorNational Taiwan University Hospital
Started2021-09-27
Est. completion2026-10
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05215548
Summary
Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival. This project is supposed to establish a new treatment protocol for stage IV NSCLC with EGFR mutation.
Eligibility
Age: 20 Years+Healthy volunteers accepted
Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer * Stage IV non-small cell lung cancer which is amenable to thoracic surgery * Patients must have one of the following:NSCLC which harbors EGFR exon 19 deletion or L858R mutation. * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Candidate for therapeutic intent surgery to at least one site of disease * Signed and dated written informed consent prior to admission to the study in accordance with International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)-Good Clinical Practice (GCP) guidelines and to the local legislation Exclusion Criteria: * Life expectancy \<= 12 weeks * With underlying diseases such as moderate to severe Chronic Obstructive Pulmonary Disease or tuberculosis * With uncontrol diseases including acute infection, unstable angina or angina in recent 3 months, Heart failure(NYHA≥2), myocardial infarction in recent 6 months, severe arrhythmia, moderate to severe cirrhosis, moderate to severe chronic renal insufficiency, immune insufficiency, any systemic disease with poor prognosis after treatment. * With Cerebrovascular Accident complicated dependent activities of daily living. * Any other cancer with active treatment in recent 5 years. * receive thoracic surgery in the ipsilateral site with the lung cancer previously. (the biopsy surgery required for the diagnosis of lung cancer was not excluded) * pregnant or breast-feeding woman * Previous treatment with other EGFR TKI. NOTE: Patients who are receiving initial afatinib (6-12 weeks) outside this study are not excluded * Disagree to receive Next Generation Sequencing for the lesion specimen after surgery.
Conditions3
CancerLung CancerNSCLC Stage IV
Interventions1
Related trials
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) — Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA — Shanghai Jiao Tong University School of Medicine
- The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute
- Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer — Jeeyun Lee
- Pemigatinib + Afatinib in Advanced Refractory Solid Tumors — Massachusetts General Hospital
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorNational Taiwan University Hospital
Started2021-09-27
Est. completion2026-10
Eligibility
Age20 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05215548